Full Text View
Tabular View
No Study Results Posted
Related Studies
Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer
This study has been completed.
Study NCT00710710   Information provided by Boehringer Ingelheim Pharmaceuticals

First Received on July 3, 2008.   Last Updated on May 28, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Pancreatic Neoplasms
Additional conditions recognized in this trial
Neoplasms
More general conditions related to this trial
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Neoplasms by Site
Pancreatic Diseases
Interventions listed in this trial
BI 2536
Sponsors listed in this trial
Boehringer Ingelheim Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services